Literature DB >> 25242818

Up-regulation of miR-146a contributes to the inhibition of invasion of pancreatic cancer cells.

Yiwei Li1, Timothy G VandenBoom1, Zhiwei Wang1, Dejuan Kong1, Shadan Ali1, Philip A Philip1, Fazlul H Sarkar1.   

Abstract

Pancreatic cancer (PC) is an aggressive malignancy with high mortality and is believed to be in part due to its highly invasive and metastatic behavior, which is associated with over-expression of EGFR and activation of NF-κB. Emerging evidence also suggest critical roles of microRNAs (miRNAs) in the regulation of various pathobiological processes including metastasis in PC and in other human malignancies. In the present study, we found lower expression of miR-146a in PC cells compared to normal human pancreatic duct epithelial (HPDE) cells. Interestingly, re-expression of miR-146a inhibited the invasive capacity of Colo357 and Panc-1 PC cells with concomitant down-regulation of EGFR and IRAK-1. Mechanistic studies including miR-146a re-expression, anti-miR-146 transfection, and EGFR knock-down experiment showed that there was a crosstalk between EGFR, MTA-2, IRAK-1, IκBα and NF-κB. Most importantly, we found that the treatment of PC cells with "natural agents" [3,3'-diinodolylmethane (DIM) or isoflavone] led to an increase in the expression of miR-146a and consequently down-regulated the expression of EGFR, MTA-2, IRAK-1 and NF-κB, resulting in the inhibition of invasion of Colo357 and Panc-1 cells. These results provide experimental evidence in support of the role of DIM and isoflavone as potential non-toxic agents as regulators of miRNA, which could be useful for the inhibition of cancer cell invasion and metastasis, and further suggesting that these agents could be important for designing novel targeted strategy for the treatment of PC.

Entities:  

Keywords:  invasion; microRNA; pancreatic cancer

Year:  2010        PMID: 25242818      PMCID: PMC4166514          DOI: 10.1158/1538-7445.AM10-5703

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Deacetylation of p53 modulates its effect on cell growth and apoptosis.

Authors:  J Luo; F Su; D Chen; A Shiloh; W Gu
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

Review 2.  NF-kappaB in pancreatic cancer.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Douglas B Evans; Paul J Chiao
Journal:  Int J Gastrointest Cancer       Date:  2003

3.  The role of microRNA genes in papillary thyroid carcinoma.

Authors:  Huiling He; Krystian Jazdzewski; Wei Li; Sandya Liyanarachchi; Rebecca Nagy; Stefano Volinia; George A Calin; Chang-Gong Liu; Kaarle Franssila; Saul Suster; Richard T Kloos; Carlo M Croce; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

4.  NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.

Authors:  Konstantin D Taganov; Mark P Boldin; Kuang-Jung Chang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-02       Impact factor: 11.205

5.  Expression of MTA2 gene in ovarian epithelial cancer and its clinical implication.

Authors:  Yuxin Ji; Ping Zhang; Yunping Lu; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

6.  Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6.

Authors:  Micah Luftig; Efthimios Prinarakis; Teruhito Yasui; Theodore Tsichritzis; Ellen Cahir-McFarland; Jun-Ichiro Inoue; Hiroyasu Nakano; Tak Wah Mak; Wen-Chen Yeh; Xiaoxia Li; Shizuo Akira; Nobutaka Suzuki; Shinobu Suzuki; George Mosialos; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

7.  Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

Authors:  Junichi Takamizawa; Hiroyuki Konishi; Kiyoshi Yanagisawa; Shuta Tomida; Hirotaka Osada; Hideki Endoh; Tomoko Harano; Yasushi Yatabe; Masato Nagino; Yuji Nimura; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

8.  Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.

Authors:  Meritxell Gironella; Mylène Seux; Min-Jue Xie; Carla Cano; Richard Tomasini; Julien Gommeaux; Stephane Garcia; Jonathan Nowak; Man Lung Yeung; Kuan-Teh Jeang; Amandine Chaix; Ladan Fazli; Yoshiharu Motoo; Qing Wang; Palma Rocchi; Antonio Russo; Martin Gleave; Jean-Charles Dagorn; Juan L Iovanna; Alice Carrier; Marie-Josèphe Pébusque; Nelson J Dusetti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

9.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

Authors:  Yiwei Li; Timothy G VandenBoom; Dejuan Kong; Zhiwei Wang; Shadan Ali; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

10.  Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth.

Authors:  Xiaohong Wang; Shuang Tang; Shu-Yun Le; Robert Lu; Janet S Rader; Craig Meyers; Zhi-Ming Zheng
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

View more
  13 in total

1.  Olaparib and enzalutamide synergistically suppress HCC progression via the AR-mediated miR-146a-5p/BRCA1 signaling.

Authors:  Jie Zhao; Yin Sun; Hui Lin; Fuju Chou; Yao Xiao; Ren'an Jin; Xiujun Cai; Chawnshang Chang
Journal:  FASEB J       Date:  2020-03-05       Impact factor: 5.191

Review 2.  Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.

Authors:  V Taucher; H Mangge; J Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2016-04-08       Impact factor: 6.730

Review 3.  miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.

Authors:  Anteneh A Tesfaye; Asfar S Azmi; Philip A Philip
Journal:  Am J Pathol       Date:  2019-01       Impact factor: 4.307

4.  Quercetin inhibits proliferation and invasion acts by up-regulating miR-146a in human breast cancer cells.

Authors:  Si-Feng Tao; Hai-Fei He; Qiang Chen
Journal:  Mol Cell Biochem       Date:  2015-01-18       Impact factor: 3.396

Review 5.  MicroRNA in pancreatic cancer.

Authors:  Keiichi Yonemori; Hiroshi Kurahara; Kosei Maemura; Shoji Natsugoe
Journal:  J Hum Genet       Date:  2016-06-02       Impact factor: 3.172

6.  CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines.

Authors:  Alessio Biagioni; Anastasia Chillà; Mario Del Rosso; Gabriella Fibbi; Francesca Scavone; Elena Andreucci; Silvia Peppicelli; Francesca Bianchini; Lido Calorini; Anna Li Santi; Pia Ragno; Francesca Margheri; Anna Laurenzana
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

7.  MiR-1178 promotes the proliferation, G1/S transition, migration and invasion of pancreatic cancer cells by targeting CHIP.

Authors:  Zhe Cao; Jianwei Xu; Hua Huang; Peng Shen; Lei You; Li Zhou; Lianfang Zheng; Taiping Zhang; Yupei Zhao
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

Review 8.  The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease Progression.

Authors:  Zuhair Hawa; Inamul Haque; Arnab Ghosh; Snigdha Banerjee; LaCoiya Harris; Sushanta K Banerjee
Journal:  Int J Mol Sci       Date:  2016-05-26       Impact factor: 5.923

Review 9.  MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer.

Authors:  Yiwei Li; Fazlul H Sarkar
Journal:  Int J Biol Sci       Date:  2016-01-28       Impact factor: 6.580

10.  miR-146a Attenuates Inflammatory Pathways Mediated by TLR4/NF-κB and TNFα to Protect Primary Human Retinal Microvascular Endothelial Cells Grown in High Glucose.

Authors:  Eun-Ah Ye; Jena J Steinle
Journal:  Mediators Inflamm       Date:  2016-02-21       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.